Treatment of the Cancer Anorexia-Cachexia Syndrome: A Critical Reappraisal

References

• Theologides A. The anorexia-cachexia syndrome. A new hyphothesis. Ann NY Acad Sci 1974; 230: 427–34.
   PubMedGoogle Scholar
• Waterhouse C. How tumors affect host metabolism. Ann NY Acad Sci 1974, 230: 89–93.
   Google Scholar
• DeWys WD, Begg C, Lavin PT et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980; 69: 491–4.
   Google Scholar
• Jaskoviak NT, Alexander RH. The pathophysiology of cancer cachexia. In: Doyle D., Hanks GVC, MacDonald N eds. Oxford Textbook of Palliative Medicine. 2nd Edition. Oxford: Oxford Medical Publications, 1998; 534–48.
   Google Scholar
• Nelson KA, Walsh D, Sheehan FA. The cancer anorex-ia-cachexia syndrome. J Clin Oncol 1994; 12 (1): 213–25.
   PubMed Web of Science ®Google Scholar
• Tisdale MJ. Metabolic abnormalities in cachexia and anorexia. Nutrition 2000, 16 (10): 1013–4.
   PubMed Web of Science ®Google Scholar
• Ciechanover A, Schwartz AL. Ubiquitin-mediated degra-dation of cellular proteins in health and in disease. Hepatology Jan 2002.
   Google Scholar
• Giacosa A, Frascio F, Sukkar SG et al. Food intake and body composition in cancer cachexia. Nutrition 1996; 12: S20–S23.
   PubMed Web of Science ®Google Scholar
• Argiles JP, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev 1999; 19 (3): 223–48.
   PubMed Web of Science ®Google Scholar
• Simons JP, Schols AM, Buurrman WA, et al. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hor-mones. Clin Sci (Lond) 1999; 97 (2): 215–23.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Maccid A, Madeddu C, et al. Role of proinflammatory cytokines and leptin in cancer-related anorex-ia/cachexia. Metabolic abnormalities and therapeutic approaches. RINPE 2002; 20 (1): 13–20.
   Google Scholar
• Laviano A, Muscaritoli M, Gianni C, et al. Neurochemical basis of cancer anorexia. RINPE 2002; 20 (1): 21–8.
   Google Scholar
• Loprinzi CL. Should cancer patients with incurable dis-ease receive parenteral or enteral nutritional support? (Bridging Editorial). Eur J Cancer 1998 ; 34 (3): 279–85.
   PubMed Web of Science ®Google Scholar
• Mercadante S. Parenteral versus enteral nutrition in cancer patients: indications and practice. Supp Care Cancer 1998; 6: 85–93.
   PubMed Web of Science ®Google Scholar
• Schneider S, Blanc-Vincent MP, Nitenberg G, et al. Standards, options and recommendations for home parenteral or enteral nutrition in adult cancer patients. Bull Cancer 2001; 88: 605–18.
   PubMed Web of Science ®Google Scholar
• Tanneberger S, Malavasi I, Mariano P, et al. Planning palliative or terminal care: the dilemma of doctors' prognoses in terminally ill cancer patients. Ann Oncol 2002; 13 (8): 1320–2.
   PubMed Web of Science ®Google Scholar
• Kardinal C, Loprinzi CL, Schaid DJ et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990; 65: 2657–62.
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Itri LM, Pisko SE et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazin in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 305: 905–9.
   PubMed Web of Science ®Google Scholar
• Bruera E, Belzile M, Neumann C, et al. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Management 2000; 19 (6): 427–35.
   PubMed Web of Science ®Google Scholar
• Kochakian CD. II Metabolic effects. In: Kochakian CD ed. Anabolic Steroids. Berlin, Springer Verlag, 1976; 5-72.
   Google Scholar
• Chlebowski RT, Herrld J, Ali I, et al. Influence of nan-drolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 1986; 58 (1): 183–6.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Maccid A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. Drugs 2001; 61 (4): 499–514.
   PubMed Web of Science ®Google Scholar
• Moertel C, Schutt AG, Reiteneier RJ, et al. Corticosteroid therapy of pre-terrninal gastrointestinal cancer. Cancer 1974; 33: 1607–9.
   PubMed Web of Science ®Google Scholar
• Willox J, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer. BMJ 1984; 200-27.
   Google Scholar
• Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69 (718): 751–4.
   PubMedGoogle Scholar
• Robustelli Della Cuna C, Pellegrini A, Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in pre-terminal cancer patients: a placebo controlled multicenter study. Eur J Cancer Clin Oncol 1989; 25: 1823–9.
   Google Scholar
• Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol 1989; 25: 1823–9.
   PubMedGoogle Scholar
• Bruera E, Roca E, Cedaro L et al. Improved control of chemotherapy-induced emesis by the addition of dexametha-sone to metoclopramide in patients resistant to metoclo-pramide. Cancer Treat Rep 1983; 67 (4): 381–3.
   Google Scholar
• Watanabe S, Bruera E. Corticosteroids as adjuvant analgesics. J Pain Symptom manage 1994; 9 (7): 442–5.
   PubMed Web of Science ®Google Scholar
• Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for can-cer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20 (2): 567–73.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Juross SA, O'Fallon JR, et al. Randomized, placebo-controlled evaluation on hydrazine sul-fate in patients with advanced colorectal cancer. J Clin Oncol 1994; 12: 1121–5.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Goldberg RM, Su JQ. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994; 12: 1126–9.
   PubMed Web of Science ®Google Scholar
• Kosty MP, Fleishman SB, Herndon JE, et al. Cisplatin, vinblastine and hydrazine sulfate in advanced non-small-cell lung cancer; a randomized placebo-controlled, double blind phase III study of the cancer and leukemia group B. J Clin Oncol 1994; 12: 1113–20.
   PubMed Web of Science ®Google Scholar
• Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996; 32A(8): 1340–3.
   PubMed Web of Science ®Google Scholar
• Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide. Drugs 2000; 60 (2): 273–92.
   PubMed Web of Science ®Google Scholar
• Agteresch HJ, Rietveld T, Kerkhofs LGM, et al. Beneficial effects of adenosine triphosphate on nutritional sta-tus in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol 2002; 20 (2): 371–8.
   PubMed Web of Science ®Google Scholar
• Gelin J, Moldawer LL, Lonnroth C, et al. Role of endogenous tumor necrosis factor a and interleukin-1 for experimetal tumor growth and the developement of cancer cachexia. Cancer Res 1991; 51: 415–21.
   PubMed Web of Science ®Google Scholar
• Pannuti F, Marton' A, Camaggi CM et al. High dose medroxyprogesterone acetate in oncology. History, clinical use and pharmacokinetics In: F. CavaIli, W.L. McGuire, F. Pannuti, A. Pellegrini, G. Robustelli della Cuna Eds. Proceedings of the Intern. Symp. on Medroxyprogesterone acetate. Amsterdam, Excerpta Medica, 1982; 5-43.
   Google Scholar
• LeIli G, Angelelli B, Giambiasi ME et al. The anabolic effect of high dose medroxyprogesterone acetate in oncology. Pharmacol Res Commun 1983; 15 (6): 561–8.
   PubMedGoogle Scholar
• LeIli G, Angelelli B, Zanichelli L et al. The effect of high dose medroxyprogesterone acetate on water and salt metabolism in advanced cancer patients. Chemioterapia 1984; 3 (5): 327–9.
   Google Scholar
• Downer S, Joel S, Albright A et al. A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 1993; 67 (5): 1102–5.
   Google Scholar
• Simons J, Aaronson NK, Vansteenkiste JF et al. Effects of medroxyprogesterone acetate on appetite, weight and quality of life in advanced stage non hormone sensitive cancer: a placebo controlled multicenter study. J Clin Oncol 1996; 14 (4): 1007–84.
   PubMedGoogle Scholar
• Loprinzi CL, Schaid DJ, Dose AM et al. Body-compo-sition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993; 11: 152–4.
   PubMed Web of Science ®Google Scholar
• Simons JP, Schols AM, Hoefnagels JM, et al. Effects of medroxiprogesterone acetate on food intake, body compo-sition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer. Cancer 1998; 82: 553–60.
   PubMed Web of Science ®Google Scholar
• Tchekmedyian NS, Tait N, Moody M et al. High dose megestrol acetate. A possible treatment for cachexia. JAMA 1987; 257 (9): 1195–8.
   Google Scholar
• Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998; 55 (5): 675–88.
   PubMed Web of Science ®Google Scholar
• Gebbia V, Testa A, Gebbia N. Prospective randomised trial of two dose levels of megestrol acetate in the manage-ment of anorexia-cachexia syndrome in patients with metasta-tic cancer. Br J Cancer 1996; 73: 1576–80.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Maccid A, Lai P et al. Cytokine activity in cancer-related anorexia/cachexia: Role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 1998; 25 (2) S6: 45-52.
   Google Scholar
• Maltoni M, Nanni O, Scarpi E et al. High-dose prog-estins for the treatment of cancer anorexia-cachexia syn-drome. A systematic review of randomized clinical trials. Ann Oncol 2001; 12: 289–300.
   Google Scholar
• Jatoi A, Yamashita J, Sloan JA, et al. Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. Support Care Cancer 2002; 10 (1): 71–5.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Kugler JW, Sloan JA et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachex-ia. J Clin Oncol 1999; 17 (10): 3299–306.
   PubMed Web of Science ®Google Scholar
• Bruera E, Sweeney C. Cachexia and astenia in cancer patients. Lancet Oncol 2000; 1: 138–47.
   PubMedGoogle Scholar
• Donnelly S, Walsh D. Low-dose megestrol acetate for appetite stimulation in advanced cancer. J Pain Symptom Mngt 1995; 10 (3): 182–3.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Michalak JC, Schaid DJ et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993; 11: 762–7.
   PubMed Web of Science ®Google Scholar
• Kurzrock R. The role of cytochines in cancer-related fatigue. Cancer 2001; 92: 1684–8.
   PubMed Web of Science ®Google Scholar
• Lundholm K, Gelin J, Hyltander A et al. Anti-inflam-matory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994; 54: 5602–6.
   Google Scholar
• Hussey HJ, Tisdale MJ. Effect of the specific cyclooxy-genase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model. Int J Cancer 2000; 87 (1): 95–100.
   PubMed Web of Science ®Google Scholar
• Purasiri P, Murray A, Richardson S, et al. Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer. Clin Sci 1994; 87: 711–7.
   PubMed Web of Science ®Google Scholar
• Wigmore SJ, Ross JA, Falconer JS, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996; 12 Suppl 1: S27–30.
   PubMed Web of Science ®Google Scholar
• Wigmore SJ, Fearon KC, Maingay JP, et al. Down-regulation of the acute-phase response in patients with pan-creatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci 1997; 92: 215–21.
   PubMed Web of Science ®Google Scholar